OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
DCGO$0.5959

DocGo Inc

Healthcare Facilities & ServicesVerified

DocGo Inc has a market capitalization of $58.39 million and a price-to-book ratio of 0.41, indicating a significant discount to its book value. The company's liquidity position is strong, with a current ratio of 2.26 and $51.02 million in cash and equivalents, which provides a buffer against short-term obligations. However, the company's free cash flow is negative at -$188.14 million, driven by a large capital expenditure of -$7.43 million and a net loss of -$182.40 million. Profitability metrics show a challenging operating environment for DocGo. The company reported a net loss of -$182.40 million and an operating loss of -$183.03 million, resulting in a return on equity of -126.66% and a return on assets of -84.02%. These figures are significantly below the industry median for healthcare facilities and services, which typically report positive returns on equity and assets. The gross profit margin of 30.65% is also below the industry median, indicating inefficiencies in cost management or pricing power. DocGo's revenue is concentrated in a single business segment, pharmaceuticals, which accounts for the entirety of its $322.20 million in revenue. There is no geographic diversification disclosed, suggesting a high concentration risk in its primary market. This lack of diversification could expose the company to regional economic downturns or regulatory changes that could impact its operations. Looking ahead, DocGo's revenue is expected to remain under pressure. The company's free cash flow is projected to remain negative, and its operating cash flow of $34.45 million is insufficient to cover its capital expenditures and net losses. Analysts have provided a mean price target of $2.10, with a median of $2.50, suggesting a potential upside from the current market price of $0.59. However, the company's financial performance and cash flow challenges may limit its ability to meet these targets in the near term. The risk assessment for DocGo indicates low liquidity and dilution risks, with no immediate filing-based flags detected. However, the company's high debt-to-equity ratio of 0.12 and negative net income suggest potential financial instability. The risk of dilution is low, but the company's negative free cash flow and high capital expenditures could necessitate additional financing in the future. Recent events and filings do not indicate any significant changes in the company's financial or operational status. The company's financial performance and cash flow challenges remain the primary focus for investors and analysts.

30-day price · DCGO-0.00 (-0.9%)
Low$0.49High$0.75Close$0.57As of10 May, 00:00 UTC
Profile
CompanyDocGo Inc
TickerDCGO.O
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. DocGo Inc provides healthcare services and equipment, primarily generating revenue through pharmaceuticals and healthcare facility operations.

Classification. DocGo is classified in the Healthcare Facilities & Services industry under the Healthcare Services & Equipment business sector, with a confidence level of 0.92.

DocGo Inc has a market capitalization of $58.39 million and a price-to-book ratio of 0.41, indicating a significant discount to its book value. The company's liquidity position is strong, with a current ratio of 2.26 and $51.02 million in cash and equivalents, which provides a buffer against short-term obligations. However, the company's free cash flow is negative at -$188.14 million, driven by a large capital expenditure of -$7.43 million and a net loss of -$182.40 million. Profitability metrics show a challenging operating environment for DocGo. The company reported a net loss of -$182.40 million and an operating loss of -$183.03 million, resulting in a return on equity of -126.66% and a return on assets of -84.02%. These figures are significantly below the industry median for healthcare facilities and services, which typically report positive returns on equity and assets. The gross profit margin of 30.65% is also below the industry median, indicating inefficiencies in cost management or pricing power. DocGo's revenue is concentrated in a single business segment, pharmaceuticals, which accounts for the entirety of its $322.20 million in revenue. There is no geographic diversification disclosed, suggesting a high concentration risk in its primary market. This lack of diversification could expose the company to regional economic downturns or regulatory changes that could impact its operations. Looking ahead, DocGo's revenue is expected to remain under pressure. The company's free cash flow is projected to remain negative, and its operating cash flow of $34.45 million is insufficient to cover its capital expenditures and net losses. Analysts have provided a mean price target of $2.10, with a median of $2.50, suggesting a potential upside from the current market price of $0.59. However, the company's financial performance and cash flow challenges may limit its ability to meet these targets in the near term. The risk assessment for DocGo indicates low liquidity and dilution risks, with no immediate filing-based flags detected. However, the company's high debt-to-equity ratio of 0.12 and negative net income suggest potential financial instability. The risk of dilution is low, but the company's negative free cash flow and high capital expenditures could necessitate additional financing in the future. Recent events and filings do not indicate any significant changes in the company's financial or operational status. The company's financial performance and cash flow challenges remain the primary focus for investors and analysts.
Key takeaways
  • DocGo Inc has a strong liquidity position with $51.02 million in cash and equivalents.
  • The company's profitability metrics are significantly below industry medians, with a return on equity of -126.66%.
  • Revenue is entirely concentrated in the pharmaceuticals segment, with no geographic diversification.
  • Analysts have provided a mean price target of $2.10, suggesting potential upside from the current market price of $0.59.
  • The company's free cash flow is negative at -$188.14 million, driven by a large capital expenditure and net loss.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$322.2M
Gross profit$98.8M
Operating income-$183.0M
Net income-$182.4M
R&D
SG&A
D&A
SBC
Operating cash flow$34.5M
CapEx-$7.4M
Free cash flow-$188.1M
Total assets$217.1M
Total liabilities$73.1M
Total equity$144.0M
Cash & equivalents$51.0M
Long-term debt$17.0M
Valuation
Market price$0.59
Market cap$58.4M
Enterprise value$24.3M
P/E
Reported non-GAAP P/E
EV/Revenue0.1
EV/Op income
EV/OCF0.7
P/B0.4
P/Tangible book0.4
Tangible book$144.0M
Net cash$34.1M
Current ratio2.3
Debt/Equity0.1
ROA-84.0%
ROE-1.3%
Cash conversion-19.0%
CapEx/Revenue-2.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricDCGOActivity
Op margin-56.8%7.7% medp25 -2.4% · p75 15.5%bottom quartile
Net margin-56.6%5.9% medp25 -3.8% · p75 12.8%bottom quartile
Gross margin30.7%45.5% medp25 31.1% · p75 62.9%bottom quartile
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-2.3%-7.0% medp25 -14.9% · p75 -3.2%top quartile
Debt / equity12.0%25.0% medp25 3.8% · p75 63.3%below median
Observations
IR observations
Mean price target2.10 USD
Median price target2.50 USD
High price target3.00 USD
Low price target1.00 USD
Mean recommendation2.33 (1=strong buy, 5=strong sell)
Strong-buy count1.00
Buy count2.00
Hold count3.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate-0.23 USD
Last actual EPS-1.84 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-16 16:00 UTC#245ef901
Market quoteclose USD 0.63 · shares 0.10B diluted
no public URL
2026-05-16 16:01 UTC#e038b0a3
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 18:12 UTCJob: 802bc71d